1. Introduction {#s0005}
===============

Cardiovascular disease has been the second most common mortality since 2000 in Taiwan [@bb0005]. Myocardial perfusion imaging (MPI) is a useful tool in diagnosing and follow up care for coronary artery disease [@bb0010]. According to current clinical guidelines for better sensitivity and specificity, the exam is performed with a stress test [@bb0010], [@bb0015], [@bb0020]. Dipyrdamole, a vasodilator, is one of the most widely used agents in stress tests in Taiwan. According to prior literature, up to 70% of patients undergoing dipyridamole stress suffer from adverse effects such as flush, chest pain, headache, dizziness, hypotension, abdominal pain, or diarrhea [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]. However, severity and duration of adverse effects have not been analyzed. As stated, the aim of this study is to examine dynamic data of dipyridamole side effects during MPS.

2. Materials and methods {#s0010}
========================

2.1. Patients and data collection {#s0015}
---------------------------------

In our institute, symptoms of patients receiving dipyridamole-stress MPI for 3 min, 10 min, and 20 min were recorded, according to the Common Terminology Criteria of Adverse Effects v4.0 (CTCAE) [@bb0050]. Records were written and maintained by physicians and technicians. Symptoms recorded included: chest tightness, palpitation, abdominal pain, diarrhea, nausea, headache, dizziness, neck pain, dyspnea, weakness, and flush. If symptoms persisted for more than 20 min after administration, we recorded timing of recovery. In the case of aminophylline use to relieve adverse effects, we also recorded administration timing.

From July 2nd 2013 to July 19th 2013, there were 183 patients receiving MPI. There were 138 complete records of symptoms after delivery of dipyridamole. For an evaluation of confounding factors, we collected the following parameters: age, gender, and frequency of regular exercise. These comorbidities were recorded in the clinical chart review: hypertension, diabetes, dyslipidemia, prior myocardial infarction (MI), documented coronary artery disease (CAD), and congestive heart failure. The laboratory data over 3 months were also recorded: creatinine level, lipid profile, and hepatic enzyme glutamate pyruvate transaminase (GPT).

These methods were approved by our institutional review board.

2.2. Stress protocol {#s0020}
--------------------

All patients underwent the Thallium-201 (Tl-201) stress and early-redistribution MPI with the dipyridamole stress test, on the recommendation of the Society of Nuclear Medicine and Molecular Imaging (SNMMI and EANM). Heart rate, blood pressure, and ECG monitoring were performed throughout the stress test.

2.3. Statistics {#s0025}
---------------

R project version 3.1.2 was used for statistical analysis. The continuous parameters were expressed in terms of mean and standard deviation (SD). The categorical variables were expressed as count and percentage. Severity of each symptom at 3 min, 10 min, and 20 min were also expressed as count and percentage.

The Kaplan-Meier curve was used to highlight persistent symptoms.

Patients were in two groups according to age (age \> 65). For an evaluation of confounding factors, e.g., gender and age, the Kaplan-Meier curve and Cox regression test were used for comparison between males and females, the age groups, and the exercise groups.

3. Results {#s0030}
==========

Data from 138 patients were analyzed and listed in [Table 1](#t0005){ref-type="table"}. The average age was 66.1 ± 13.4 years (range 32--90). Seventy-five were male (54.3%) and 60 study subjects exercised more than 3 times per week (43.5%). There were 96 patients (69.6%) suffering from symptoms of drug side effects during observation. Between the symptomatic and asymptomatic group, the incidence of comorbidities and lab data were not statistically different, except that the serum creatinine level was higher in the asymtomatic group. However, in the symptomatic group, the ratio of female patients was significantly higher than in the asymptomatic group (*p* = 0.002141), while the age was significantly younger (*p* = 0.009262).Table 1Patient background information.Table 1TotalSymptomaticAsymptomaticP-valueNumber1389642Gender0.002141 Male75 (54.3%)41 (42.7%)33 (78.6%) Female63 (45.7%)55 (57.3%)9 (21.4%)Age (years old)66.1 ± 13.4 (32-90)64.2 ± 13.24 (32-90)70.6 ± 12.88 (41-90)0.009262Frequency of exercise\
(times per week) Range0-7 Median1 Mean2.82.92.50.4626 ≥ 360 (43.5%)Using aminophylline18 Timing (min)22.2 ± 8.5Comorbidity Hypertension85 (61.6%)56 (58.3%)29 (69.0%)0.317 Diabetes37 (26.8%)24 (25.0%)13 (31.0%)0.6048 Dyslipidemia51 (37.0%)34 (35.4%)17 (40.5%)0.7077 Prior MI22 (15.9%)14 (14.6%)8 (19.0%)0.6844 Documented CAD39 (28.3%)23 (24.0%)16 (38.1%)0.1358 Congestive heart failure10 (7.2%)7 (7.3%)3 (7.1%)1 Creatinine (n = 125)1.37 ± 1.07 (0.57--6.87)1.19 ± 0.77 (0.57--6.69)1.79 ± 1.49 (0.81--6.06)0.02368 HDL (n = 111)40.31 ± 10.52 (19--77)40.83 ± 10.83 (22--77)39.17 ± 9.88 (19--59)0.4284 LDL (n = 111)97.52 ± 29.16 (41--218)97.17 ± 27.07 (41--195)98.29 ± 33.69 (48--218)0.8642 TG (n = 106)155.95 ± 113.54 (35--769)162.07 ± 108.49 (42--69)142.42 ± 124.68 (35--552)0.438 GPT (n = 119)29.77 ± 26.98 (4--261)29.66 ± 17.7 (6--101)30.03 ± 41.48 (4--261)0.9597 Pretest SBP150.95 ± 22 (101--214)150.25 ± 23.32 (101--214)152.57 ± 18.82 (110--183)0.5392 Pretest DBP86.88 ± 12.3 (57--126)86.87 ± 13.43 (57--126)86.90 ± 9.40 (71--106)0.9876 Post test SBP130.8 ± 18.27 (94--188)132.02 ± 19.37 (94--188)128.02 ± 15.29 (94--164)0.1971 Post test DBP75.21 ± 11.87 (49--113)75.8 ± 12.37 (52--113)73.86 ± 110.65 (49--95)0.3505

The frequency and severity of adverse effects are listed in [Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}. Adverse effects occurred in 96 patients (69.6%), with the most frequent symptoms being dizziness (42.8%), chest tightness (24.6%), abdominal pain (18.1%), and headache (15.2%). These effects accompany dyspnea (8.7%), nausea (8.0%), neck pain (7.2%), weakness (5.1%), palpitation (3.6%), and flush (2.9%). No patients had diarrhea in our study population, while most symptoms were Grade 1 and 2. Seven patients had Grade 3 symptoms as shown in [Table 6](#t0030){ref-type="table"}. There were 18 patients receiving aminophylline treatment due to adverse effects. For patients with symptoms at 3 min, the persistent symptoms can be seen in the Kaplan-Meier curve ([Fig. 2](#f0010){ref-type="fig"}). The median duration of persistent symptoms was 36 min (95% confidence interval \[CI\]: 30--46 min). Fifty-six patients (40.6%) did not recover from side effects at 20 min, while 32 of them were female.Fig. 1Severity of adverse effects after dipyridamole infusion at 3 different points. Grading is based on CTCAE v4.0.Fig. 1Fig. 2For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier curve.Fig. 2Table 2Number and percentage of symptoms at 3, 10, and 20 min.Table 23rd minute10th minute20th minuteAny timeChest tightness26 (18.8%)24 (17.4%)17 (12.3%)34 (24.6%)Palpitation4 (2.9%)2 (1.4%)2 (1.4%)5 (3.6%)Abdominal pain13 (9.4%)19 (13.8%)7 (5.1%)25 (18.1%)Dyspnea10 (7.3%)7 (5.1%)4 (2.9%)12 (8.7%)Diarrhea0000Nausea5 (3.6%)7 (5.1%)7 (5.1%)11 (8.0%)Headache16 (11.6%)13 (9.4%)11 (8.0%)21 (15.2%)Dizziness52 (37.7%)45 (32.6%)30 (21.7%)59 (42.8%)Neck pain5 (3.6%)5 (3.6%)8 (5.8%)10 (7.2%)Weakness3 (2.2%)6 (4.3%)7 (5.1%)7 (5.1%)Flush3 (2.2%)1 (0.7%)1 (0.7%)4 (2.9%)Overall84(60.9%)79 (57.2%)56 (40.6%)96 (69.6%)

There was a significantly higher incidence of adverse effects in the female population than the male population at all points ([Table 1](#t0005){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). There is a higher incidence in women for the three time points of dizziness, chest tightness, abdominal pain, headache, dyspnea, nausea, weakness, and palpitation. However, there is a significant difference between genders for dizziness only at 10 min.Table 3Incidence of symptomatic patients at 3, 10, and 20 min for gender.Table 3Male (n = 75)Female (n = 63)*p* value3rd minute35 (46.7%)49 (77.8%)0.000378^⁎^ Chest tightness10 (13.3%)16 (25.4%)0.1126 Palpitation1 (1.3%)3 (4.8%)0.4924 Abdominal pain6 (8.0%)7 (11.1%)0.7409 Dyspnea3 (4.0%)7 (11.1%)0.2022 Diarrhea00-- Nausea1 (1.3%)4 (6.3%)0.2656 Headache7 (9.3%)9 (14.3%)0.5233 Dizziness24 (32.0%)27 (42.9%)0.2546 Neck pain1 (1.3%)4 (6.3%)0.2659 Weakness03 (4.8%)0.1853 Flush2 (2.7%)1 (1.6%)110th minute32 (42.7%)46 (73.0%)0.0006497^⁎^ Chest tightness10 (13.3%)14 (22.2%)0.2515 Palpitation1 (1.3%)1 (1.6%)1 Abdominal pain8 (10.7%)11 (17.5%)0.3651 Dyspnea1 (1.3%)6 (9.5%)0.07271 Diarrhea00-- Nausea2 (2.7%)5 (7.9%)0.3097 Headache6 (8.0%)7 (11.1%)0.7409 Dizziness16 (21.3%)29 (46.0%)0.003724^⁎^ Neck pain3 (4.0%)2 (3.2%)1 Weakness1 (1.3%)5 (7.9%)0.14 Flush1 (1.3%)0120th minute24 (32.0%)32 (50.8%)0.03888^⁎^ Chest tightness7 (9.3%)10 (15.9%)0.3658 Palpitation1 (1.3%)1 (1.6%)1 Abdominal pain1 (1.3%)6 (9.5%)0.07271 Dyspnea1 (1.3%)3 (4.8%)0.4924 Diarrhea00-- Nausea2 (2.7%)5 (7.9%)0.3097 Headache5 (6.7%)6 (9.5%)0.7628 Dizziness12 (16.0%)18 (28.8%)0.115 Neck pain4 (5.3%)4 (6.3%)1 Weakness2 (2.7%)5 (7.9%)0.3097 Flush01 (1.6%)0.9302Any time42 (56.0%)54 (85.7%)0.0003269^⁎^ Chest tightness14 (18.7%)20 (31.7%)0.1146 Palpitation2 (2.7%)3 (4.8%)0.8424 Abdominal pain11 (14.7%)14 (22.2%)0.3544 Dyspnea3 (4.0%)9 (14.3%)0.06684 Diarrhea00-- Nausea3 (4.0%)8 (12.7%)0.1179 Headache8 (10.7%)13 (20.6%)0.1657 Dizziness25 (33.3%)34 (54.0%)0.02333^⁎^ Neck pain4 (5.3%)6 (9.5%)0.5378 Weakness2 (2.7%)5 (7.9%)0.3097 Flush2 (2.7%)2 (3.2%)1

There is no significant difference of symptom duration between genders ([Fig. 3](#f0015){ref-type="fig"}), as the *p* value of the Cox regression is 0.421. The median time for symptom-relief took 33 min for women and 36 min for men. Women tend to have a higher incidence of adverse effects, and more severe symptoms. There is a significant difference in dizziness between the two groups at 10 min (*p* = 0.003724).Fig. 3For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier curve. There is no difference between genders.Fig. 3

Younger patients (age \< 65) tended to have a higher probability of adverse effects than older patients, which was the only statistically significant difference at 3 min ([Table 4](#t0020){ref-type="table"}). The younger group had a greater risk for all symptoms except dizziness. Symptom duration was similar between age groups ([Fig. 4](#f0020){ref-type="fig"}), and *p* = 0.374. The median time of symptom-relief took 33 min in older people and 48 min in younger people. Younger people also had a higher incidence of adverse effects and more severe symptoms. There was not a significant difference for chest tightness and nausea between the two groups at 3 min (*p* = 0.000162). Exercise did not interfere with adverse dipyridamole effects in our study. (See [Table 5](#t0025){ref-type="table"}.)Fig. 4For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier curve. There is no difference between genders.Fig. 4Table 4Incidence of symptomatic patients at 3, 10, and 20 min for age.Table 4Age \< 65 (n = 63)Age ≥ 65 (n = 75)*p* value3rd minute46 (73.0%)38 (50.7%)0.01226^⁎^ Chest tightness21 (33.3%)5 (6.7%)0.000162^⁎^ Palpitation3 (4.8%)1 (1.3%)0.4924 Abdominal pain8 (12.7%)5 (6.7%)0.3598 Dyspnea6 (9.5%)4 (5.3%)0.5378 Diarrhea00-- Nausea5 (7.9%)00.04257^⁎^ Headache11 (17.5%)5 (6.7%)0.08804 Dizziness22 (34.9%)29 (38.7%)0.7817 Neck pain4 (6.3%)1 (1.3%)0.2656 Weakness2 (3.2%)1 (1.3%)0.8785 Flush2 (3.2%)1 (1.3%)0.878510th minute41 (65.1%)37 (49.3%)0.09175 Chest tightness15 (23.8%)9 (12.0%)0.1101 Palpitation1 (1.6%)1 (1.3%)1 Abdominal pain10 (15.9%)9 (12.0%)0.682 Dyspnea4 (6.3%)3 (4.0%)0.8126 Diarrhea00-- Nausea6 (9.5%)1 (1.3%)0.07271 Headache9 (14.3%)4 (5.3%)0.1334 Dizziness21 (33.3%)24 (32.0%)1 Neck pain4 (6.3%)1 (1.3%)0.2656 Weakness4 (6.3%)2 (2.7%)0.5237 Flush1 (1.6%)00.930220th minute30 (47.6%)26 (34.7%)0.1709 Chest tightness11 (17.5%)6 (8.9%)0.1543 Palpitation1 (1.6%)1 (1.3%)1 Abdominal pain2 (3.2%)5 (6.7%)0.588 Dyspnea2 (3.2%)2 (2.7%)1 Diarrhea00-- Nausea5 (7.9%)2 (2.7%)0.3097 Headache8 (12.7%)3 (4.0%)0.1179 Dizziness13 (20.6%)17 (22.7%)0.9354 Neck pain4 (6.3%)4 (5.3%)1 Weakness4 (6.3%)3 (4.0%)0.8126 Flush1 (1.6%)00.9302Any time47 (74.6%)49 (65.3%)0.3206 Chest tightness22 (34.9%)12 (16.0%)0.01774^⁎^ Palpitation4 (6.3%)1 (1.3%)0.2656 Abdominal pain12 (19.0%)13 (17.3%)0.9692 Dyspnea8 (12.7%)4 (5.3%)0.2201 Diarrhea00-- Nausea9 (14.3%)2 (2.7%)0.2818 Headache13 (20.6%)8 (10.7%)0.1657 Dizziness24 (38.1%)35 (46.7%)0.4003 Neck pain5 (7.9%)5 (6.7%)1 Weakness4 (6.3%)3 (4.0%)0.8126 Flush3 (4.8%)1 (1.3%)0.4924Table 5Number and percentage of symptomatic patients at 3, 10~,~ and 20 min in two different lifestyle groups.Table 5Weekly exercise \< 3 timesWeekly exercise \> 3 times*p* value3rd minute47 (60.3%)37 (61.7%)110th minute44 (56.4%)34 (56.7%)120th minute33 (42.3%)23 (38.3%)0.7669Any time53 (67.9%)43 (71.7%)0.7764Table 6List of patients with Grade 3 symptoms.Table 6\#GenderAgeMajor symptomsAssociated symptomsTreatmentTiming of resolution1M60Chest tightnessAminophylline at 13th minute20th minute6F70DyspneaDizziness (grade 2)Aminophylline at 17th minute20th minute31F55Chest tightness, abdominal painNausea after aminophylline (grade 3 at 20th minute)Aminophylline at 12th minute20th minute33M82Chest tightnessAminophylline at 19th minute20th minute35M46Weakness26th minute55F60Chest tightness and headacheAminophylline at 18th minute20th minute74F63NauseaChest tightness (Grade 1), dizziness (grade 1) and flush (Grade 2)Aminophylline at 25th minute25th minute

4. Discussion {#s0035}
=============

The purpose of the MPI stress test is to induce a distinction in blood flow between normal coronary arteries and those with stenosis. Dipyridamole has been used as a pharmaceutical method of stress testing. Dipyridamole infusion blocks reabsorption and metabolism of endogenic adenosine [@bb0055], [@bb0060], elevates extra-cellular adenosine concentration [@bb0060], [@bb0065], non-selectively activates all types of adenosine receptors [@bb0060], induces vascular resistance of normal coronary artery decrease, and creates myocardial blood flow increase up to 5-fold [@bb0055], [@bb0060], [@bb0065]. On the other hand, the blood flow of the myocardium, which is supplied by stenosed coronary arteries, was unable to increase blood flow from the stress due to compensatory dilation at rest [@bb0055], [@bb0060]. Dipyridamole-stress MPI is able to detect coronary artery disease as accurately as exercise stress tests, and provides prognostic information regarding cardiac death and myocardial infarction [@bb0055].

Using dipyridamole in myocardial perfusion is generally safe [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0065], [@bb0070]. Nevertheless, up to 70% of patients undergoing dipyridamole stress suffer from variable adverse effects, such as flush, chest pain, headache, dizziness, hypotension, abdominal pain, or diarrhea [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]. Adverse effects can develop from stimulating different types of adenosine receptors and signal pathways, including peripheral vasodilation and hypotension [@bb0060].

In our study population, 69.6% of patients suffered from the adverse effects of dipyridamole. The most frequent symptoms were dizziness, chest tightness, abdominal pain, and headache. Prior literature shows the incidence of adverse effects from dipyridamole can range from 27.9% to 75.36% [@bb0025], [@bb0030], [@bb0035], [@bb0045], [@bb0075], [@bb0080], [@bb0085]. However, there is a wide variation of the definition of adverse effects among studies.

The half-life of dipyridamole is approximately 30--45 min [@bb0060]. In our study, the median duration of persistent symptoms was 36 min. Duration of symptoms was not significantly different between gender and age group.

In our study population, the most frequent symptom was dizziness, which made up 42.8% of patients. Most of the symptoms were Grade 1, although nobody suffered from severe dizziness (Grade 3). A study by Takeishi et al. revealed similar results, i.e., that the incidence of dizziness from dypiridamole-stress MPI was 51% [@bb0085]. In contrast, Colarinha et al. showed that 13 individuals out of 140 patients (9.3%) undergoing dypiridamole-stress MPI experienced dizziness [@bb0080]. The variation may have resulted from different awareness levels of it.

The second most frequent symptom was chest tightness, with an accumulated incidence of 24.6%. It is much higher than found in prior studies, ranging from 0.68% to 16.4% [@bb0025], [@bb0030], [@bb0065], [@bb0075], [@bb0080], but lower than the results of Takeishi et al [@bb0085]. Most of our patients suffered from mild chest tightness, although only 12 patients (8.7%) had chest tightness greater or equal to Grade 2, and only four people (2.9%) had Grade 3 chest tightness. Dipyridamole-induced chest tightness has been correlated with more severe coronary artery disease [@bb0085].

According to our data, females have a greater potential to experience adverse effects ([Table 3](#t0015){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}). This phenomenon is revealed in a prior study [@bb0030], [@bb0040], [@bb0090]. Our data revealed that women have a higher accumulated risk for all symptoms. However, there is a statistically significant difference in dizziness at 10 min, similar to the results of Kong et al. [@bb0090]. Prior reports show that adenosine-induced adverse effects are higher in women [@bb0095], [@bb0100], [@bb0105]. The gender difference is not yet clear, but could possibly be related to different fat-to-muscle ratio [@bb0090].

In our study population, younger subjects have greater potential to have adverse effects, except for dizziness ([Table 4](#t0020){ref-type="table"}). A report from Lette et al. revealed that the frequency of dipyridamole-induced side effects is less in patients older than 70 [@bb0040]. Adenosine-related side effects also occur more frequently in younger people [@bb0110]. Our data shows, compared to those older than 65, that younger people have higher risk of all symptoms, except dizziness. There is a significant difference of chest tightness and nausea between the two age groups, but only at 3 min.

The limitation of our study includes a retrospective study design with some missing data (24.6%), and a relatively small population. Due to these issues, we did not record symptom onset more than 20 min after the dipyridamole injection, and as such, any delayed adverse effects were not evaluated.

5. Conclusion {#s0040}
=============

Our study reveals that dipyridamole use in MPS is generally safe. Women and younger people tended to have a higher risk of adverse effects. However, there is a trend that the elderly have a higher risk of dizziness than younger people. Duration of adverse effects was not significantly different for gender and age.
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